SCHEMBL2643766

SCHEMBL2643766

Cc1csc(NC(=O)c2cc(Oc3ccccc3)cc(Oc3ccccc3)c2N)n1

nearest known ligand 0.74

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 18/20 0.74
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642257 0.91 GCK (0.61) GCKNPC1RAB9A
SCHEMBL2642545 0.90 GCK (0.76) GCK
SCHEMBL2642904 0.78 GCK (0.80) GCKNPC1RAB9A
SCHEMBL2642949 0.77 GCK (0.81) GCKNPC1RAB9A
SCHEMBL2643117 0.77 GCK (1.00) GCKNPC1RAB9A
SCHEMBL2643522 0.77 GCK (0.84) GCK
SCHEMBL2643973 0.76 GCK (0.80) GCKNPC1RAB9A
SCHEMBL2642942 0.75 GCK (0.82) GCK
SCHEMBL2643497 0.75 GCK (1.00) GCK
SCHEMBL2643299 0.75 GCK (0.77) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496052-B1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-08-05 — — EP disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-20050282815-A1 Novel aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-12-22 — — US disclosed
EP-1496052-A1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-01-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282815-A1 Novel aminobenzamide derivative GCKR, GCK, HK2 GCK 2/4885NPC1 4025/4885RAB9A 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback